Please login to the form below

Not currently logged in

Earnings increase for Takeda

Japan-based Takeda Pharmaceutical has recorded an increase in net income of 17.9 per cent in its financial report for the second quarter of 2011

Japan-based Takeda Pharmaceutical has recorded an increase in profit of 17.9 per cent in its financial report for the second quarter of 2011. 

The company made 75.58bn yen for the period compare to 64.11bn Yen the previous year. 

Operating income was also up, increasing 8.3 per cent to 116.21bn yen. Launches for the company during the quarter included hypertension treatment Edarbi (azilsartan medoxomil), with growth for multiple myeloma treatment Velcade (bortezomib) and type 2 diabetes drug Actos (pioglitazone) also contributing towards a net sales increase of 0.7 per cent. 

In its outlook for future prospects, the company said it had formulated its '2011 - 2013 Mid-Range Plan'. 

The plan states that Takeda will invest greatly in research and development that is focused on its core therapeutic areas of metabolic conditions, oncology and the central nervous system. The company will also make significant investments in emerging markets.

Recent developments include the company's acquisition of Nycomed, which is pending review and expected to be completed by the end of September 2011.

In its review, Takeda said the Nycomed purchase would bring an “immediate and stable increase in cash flow,” as well as offering greater leverage for research and development. 

29th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....